| Lisa Paula Viveiros, NP | |
|
235 N Pearl St, Brockton, MA 02301-1794 | |
| (617) 835-7379 | |
| Not Available |
| Full Name | Lisa Paula Viveiros |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 18 Years |
| Location | 235 N Pearl St, Brockton, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245365949 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 251293 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Steward Medical Group Inc | 2860688728 | 1404 |
News Archive
The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.
Embracing revolutionary new techniques and answering questions about research funding are just two of the challenges facing the scientific community in the 21st century.
Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.
Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.
› Verified 9 days ago
| Entity Name | Sound Physicians Of Massachusetts Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740678408 PECOS PAC ID: 2062554637 Enrollment ID: O20100120000133 |
News Archive
The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.
Embracing revolutionary new techniques and answering questions about research funding are just two of the challenges facing the scientific community in the 21st century.
Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.
Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.
› Verified 9 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000007 |
News Archive
The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.
Embracing revolutionary new techniques and answering questions about research funding are just two of the challenges facing the scientific community in the 21st century.
Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.
Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.
› Verified 9 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000332 |
News Archive
The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.
Embracing revolutionary new techniques and answering questions about research funding are just two of the challenges facing the scientific community in the 21st century.
Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.
Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.
› Verified 9 days ago
| Entity Name | Steward Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780971275 PECOS PAC ID: 0244401404 Enrollment ID: O20110919000768 |
News Archive
The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.
Embracing revolutionary new techniques and answering questions about research funding are just two of the challenges facing the scientific community in the 21st century.
Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.
Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.
› Verified 9 days ago
| Entity Name | Carepoint Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033482864 PECOS PAC ID: 7517121361 Enrollment ID: O20120607000485 |
News Archive
The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.
Embracing revolutionary new techniques and answering questions about research funding are just two of the challenges facing the scientific community in the 21st century.
Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.
Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.
› Verified 9 days ago
| Entity Name | Carecentral Urgent Care Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922385319 PECOS PAC ID: 5496907099 Enrollment ID: O20121205000544 |
News Archive
The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.
Embracing revolutionary new techniques and answering questions about research funding are just two of the challenges facing the scientific community in the 21st century.
Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.
Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.
› Verified 9 days ago
| Entity Name | Sound Physicians Of Massachusetts Ii Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306376397 PECOS PAC ID: 9436421567 Enrollment ID: O20170823003703 |
News Archive
The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.
Embracing revolutionary new techniques and answering questions about research funding are just two of the challenges facing the scientific community in the 21st century.
Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.
Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lisa Paula Viveiros, NP 40 Louise Rd, Braintree, MA 02184-5902 Ph: (781) 817-6122 | Lisa Paula Viveiros, NP 235 N Pearl St, Brockton, MA 02301-1794 Ph: (617) 835-7379 |
News Archive
The current study suggests that deferring the second vaccination of individuals with prior infection may be a cost-effective strategy.
Embracing revolutionary new techniques and answering questions about research funding are just two of the challenges facing the scientific community in the 21st century.
Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.
Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.
› Verified 9 days ago
Dr. Peggy Mentor, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 940 Belmont St, Brockton, MA 02301 Phone: 857-364-4418 Fax: 774-826-3157 | |
Dr. Kevin Raymond Gendreau, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 Liberty St, Brockton, MA 02301 Phone: 508-894-0400 Fax: 508-565-0097 | |
Mrs. Jessica Dasilva, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1020 Pleasant St, Brockton, MA 02301 Phone: 508-586-7706 | |
Miss Jessica Chang Lim, F.N.P. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 111 Torrey St, Brockton, MA 02301 Phone: 508-588-1200 Fax: 508-941-0497 | |
Ms. Lindsay Jill Kaplan, FNP-BC Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Pearl St Ste 2100, Brockton, MA 02301 Phone: 508-897-6040 | |
Christine Murcott, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 63 Main St, Brockton, MA 02301 Phone: 508-559-6699 | |
Sasikala Sannapareddy, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 63 Main St, Brockton, MA 02301 Phone: 508-559-6699 Fax: 508-583-4649 |